论文部分内容阅读
目的探究新生儿缺氧缺血性脑病采用单唾液酸神经节苷脂注射液治疗的临床疗效及其用药安全性。方法 54例新生儿缺氧缺血性脑病患儿,采用随机数字表法分为对照组和观察组,各27例。对照组患儿给予常规治疗,观察组给予单唾液酸神经节苷脂注射液联合常规治疗,观察对比两种不同治疗方法的应用效果。结果治疗后,观察组和对照组患儿治疗总有效率分别为96.3%和77.8%,两组比较差异具有统计学意义(P<0.05)。治疗后观察组和对照组患儿新生儿神经行为测定(NBNA)评分较治疗前显著升高(P<0.05),且观察组患儿NBNA评分高于对照组(P<0.05)。用药后两组患儿不良反应发生率比较差异无统计学意义(P>0.05)。结论新生儿缺氧缺血性脑病采用单唾液酸神经节苷脂注射液治疗,可有效缓解或改善患儿临床症状,提高其NBNA评分,降低患儿不良反应发生率,治疗效果良好,具有较高的临床推广价值。
Objective To investigate the clinical efficacy and safety of monosialoganglioside injection in neonatal hypoxic-ischemic encephalopathy. Methods Fifty-four neonates with hypoxic-ischemic encephalopathy were divided into control group and observation group by random number table, with 27 cases in each group. The control group of children given conventional treatment, the observation group given monosialoganglioside injection combined with conventional treatment, observed and compared the application of two different treatment methods. Results After treatment, the total effective rate in treatment group and control group was 96.3% and 77.8%, respectively. There was significant difference between the two groups (P <0.05). After treatment, NBNA scores in observation group and control group were significantly higher than those before treatment (P <0.05), and NBNA score in observation group was higher than that in control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups after treatment (P> 0.05). Conclusion Neonatal hypoxic ischemic encephalopathy treated with monosialoganglioside injection can effectively alleviate or improve the clinical symptoms of children, improve their NBNA score, reduce the incidence of adverse reactions in children, the treatment effect is good, with more High clinical promotion value.